Clinical Trials
43 trialsErlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers
Hunan Province Tumor Hospital
MILES-3
National Cancer Institute, Naples
MILES-4
National Cancer Institute, Naples
TRUMP
Guangdong Association of Clinical Trials
DYNAPET
Fifth Affiliated Hospital, Sun Yat-Sen University
EPIC
University of Turin, Italy
Neoafa
Fifth Affiliated Hospital, Sun Yat-Sen University
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
Sungkyunkwan University
EMERGING
Guangdong Association of Clinical Trials
Endostar First-line Treatment of Advanced NSCLC
China Medical University, China
LCKY2015-21(x)
The First Affiliated Hospital of Dalian Medical University
EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism
Shanghai Pulmonary Hospital, Shanghai, China
Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients
Xinqiao Hospital of Chongqing
Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance
Tongji University
EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism
Shanghai Pulmonary Hospital, Shanghai, China
D-CIK Combined With Chemotherapy for Non-Small Cell Lung Cancer(NSCLC)
Shenzhen Hornetcorn Bio-technology Company, LTD
Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients
Shenzhen Hornetcorn Bio-technology Company, LTD
Endostar Continued Pumping Into Vein Combining With Gemcitabine-Carboplatin to Treat Non-Small Cell Lung Cancer (NSCLC)
Hunan Province Tumor Hospital
BRAVO
Tongji University
Vinorelbine and/or Gemcitabine in Treating Older Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation
Xinjiang Medical University
Gemcitabine Plus Supportive Care in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Hospitalization Rates of Patients With Non-Small Cell Lung Cancer Treated With Gemcitabine and Either Cisplatin or Carboplatin
National Cancer Institute (NCI)
AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Gemcitabine in Combination With Either Cisplatin or Carboplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Gemcitabine and Cisplatin Before or After Surgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Pemetrexed/Cisplatin Versus Gemcitabine/Cisplatin According to Thymidylate Synthase Expression
Samsung Medical Center
MAGICAL
Tongji University
FR-WB-TT/che
The University of Texas Health Science Center, Houston
First-Line Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Adjuvant Gemcitabine Plus Oxaliplatin Versus Gemcitabine Plus Cisplatin for Completely Resected Stage IB/II/IIIA NSCLC
National Cancer Center, Korea
Gemcitabine Plus Oxaliplatin in Advanced Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
National Cancer Center, Korea
DO201001
Third Military Medical University
Biweekly Gemcitabine and Docetaxel as First Line Treatment for Advanced Disease in Elderly Non-Small Cell Lung Cancer (NSCLC) Patients
Hospital Arnau de Vilanova
Biweekly Gemcitabine and Docetaxel as First Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
Hospital Arnau de Vilanova
A Study of Weekly Docetaxel Plus Cisplatin Followed by Gemcitabine vs. Gemcitabine Plus Cisplatin Followed by Weekly Docetaxel in the Treatment of Advanced Non-Small-Cell Lung Cancer
Far Eastern Memorial Hospital
Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Gemcitabine and Docetaxel in Treating Patients With Inoperable Stage IIIB or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Study of Developing an Optimal Gemcitabine Based Regimen to Treat Elderly Patients With Advanced Non-Small Cell Carcinoma
Ulsan University Hospital
Random Trial for Elderly Patients With NSCLC
Inje University
Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer
St. John Providence Health System